{"id":91115,"date":"2026-05-19T17:54:19","date_gmt":"2026-05-19T12:24:19","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=91115"},"modified":"2026-05-19T17:54:21","modified_gmt":"2026-05-19T12:24:21","slug":"emcure-pharmaceuticals-analyst-review-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-analyst-review-2026\/","title":{"rendered":"Emcure Pharmaceuticals Analyst Review May 2026"},"content":{"rendered":"<p>This <strong><a href=\"https:\/\/univest.in\/user\/stocks\/emcure\/emcure-pharmaceuticals-ltd-share-price-today\">Emcure Pharmaceuticals<\/a> analyst review<\/strong> for May 2026 covers the key data investors need for EMCURE at its current price of Rs 1,685.00. Emcure Pharmaceuticals (NSE: EMCURE) is a leading Indian pharma company with a market capitalisation of approximately Rs 11,000 crore, known for its gynaecology, HIV, and cardiology branded formulations. The analyst consensus target of Rs 2,100 implies meaningful upside, and this <strong>Emcure Pharmaceuticals analyst review<\/strong> examines technical levels, business segments, valuation, and key risks for EMCURE through FY27.<\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-analyst-review-2026\/#Emcure_Pharmaceuticals_Company_Snapshot_May_2026\" title=\"Emcure Pharmaceuticals Company Snapshot May 2026\">Emcure Pharmaceuticals Company Snapshot May 2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-analyst-review-2026\/#Analyst_Insight_in_This_Emcure_Pharmaceuticals_Analyst_Review\" title=\"Analyst Insight in This Emcure Pharmaceuticals Analyst Review\">Analyst Insight in This Emcure Pharmaceuticals Analyst Review<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-analyst-review-2026\/#Technical_Analysis_in_This_Emcure_Pharmaceuticals_Analyst_Review\" title=\"Technical Analysis in This Emcure Pharmaceuticals Analyst Review\">Technical Analysis in This Emcure Pharmaceuticals Analyst Review<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-analyst-review-2026\/#Key_Support_and_Resistance_Levels\" title=\"Key Support and Resistance Levels\">Key Support and Resistance Levels<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-analyst-review-2026\/#Business_Segment_Analysis\" title=\"Business Segment Analysis\">Business Segment Analysis<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-analyst-review-2026\/#India_Branded_Formulations_Gynaecology_Cardiology\" title=\"India Branded Formulations (Gynaecology, Cardiology)\">India Branded Formulations (Gynaecology, Cardiology)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-analyst-review-2026\/#HIV_Treatment_Drugs_Hetero_JV_Partnership\" title=\"HIV Treatment Drugs (Hetero JV Partnership)\">HIV Treatment Drugs (Hetero JV Partnership)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-analyst-review-2026\/#International_Operations_Brazil_Canada_Europe\" title=\"International Operations (Brazil, Canada, Europe)\">International Operations (Brazil, Canada, Europe)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-analyst-review-2026\/#Valuation_in_This_Emcure_Pharmaceuticals_Analyst_Review\" title=\"Valuation in This Emcure Pharmaceuticals Analyst Review\">Valuation in This Emcure Pharmaceuticals Analyst Review<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-analyst-review-2026\/#Trade_Outlook_for_Emcure_Pharmaceuticals\" title=\"Trade Outlook for Emcure Pharmaceuticals\">Trade Outlook for Emcure Pharmaceuticals<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-analyst-review-2026\/#Key_Risks_for_Emcure_Pharmaceuticals_in_FY27\" title=\"Key Risks for Emcure Pharmaceuticals in FY27\">Key Risks for Emcure Pharmaceuticals in FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-analyst-review-2026\/#Conclusion_Emcure_Pharmaceuticals_Analyst_Review_Verdict_for_2026\" title=\"Conclusion: Emcure Pharmaceuticals Analyst Review Verdict for 2026\">Conclusion: Emcure Pharmaceuticals Analyst Review Verdict for 2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-analyst-review-2026\/#Frequently_Asked_Questions_Emcure_Pharmaceuticals_Analyst_Review_2026\" title=\"Frequently Asked Questions: Emcure Pharmaceuticals Analyst Review 2026\">Frequently Asked Questions: Emcure Pharmaceuticals Analyst Review 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-analyst-review-2026\/#What_is_the_analyst_target_for_Emcure_Pharmaceuticals_in_2026\" title=\"What is the analyst target for Emcure Pharmaceuticals in 2026?\">What is the analyst target for Emcure Pharmaceuticals in 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-analyst-review-2026\/#Is_Emcure_Pharmaceuticals_a_good_investment_at_Rs_168500\" title=\"Is Emcure Pharmaceuticals a good investment at Rs 1,685.00?\">Is Emcure Pharmaceuticals a good investment at Rs 1,685.00?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-analyst-review-2026\/#What_is_Emcure_Pharmaceuticalss_52-week_high_and_low\" title=\"What is Emcure Pharmaceuticals&#8217;s 52-week high and low?\">What is Emcure Pharmaceuticals&#8217;s 52-week high and low?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-analyst-review-2026\/#What_are_the_key_risks_for_Emcure_Pharmaceuticals\" title=\"What are the key risks for Emcure Pharmaceuticals?\">What are the key risks for Emcure Pharmaceuticals?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/emcure-pharmaceuticals-analyst-review-2026\/#Where_can_I_track_live_data_for_Emcure_Pharmaceuticals\" title=\"Where can I track live data for Emcure Pharmaceuticals?\">Where can I track live data for Emcure Pharmaceuticals?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Emcure_Pharmaceuticals_Company_Snapshot_May_2026\"><\/span><strong>Emcure Pharmaceuticals Company Snapshot May 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Emcure&#8217;s branded formulations in gynaecology (Zurig, Cycloreg) are market leaders. The HIV business (Hetero JV) and international operations in Brazil, Canada, and Europe add meaningful diversification to this branded-first pharma business. The table below summarises the key data referenced in this <strong>Emcure Pharmaceuticals analyst review<\/strong>.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Parameter<\/th>\n<th>Value<\/th>\n<\/tr>\n<tr>\n<td>NSE Ticker<\/td>\n<td>EMCURE<\/td>\n<\/tr>\n<tr>\n<td>Sector<\/td>\n<td>Pharmaceuticals &#8211; Branded and Global<\/td>\n<\/tr>\n<tr>\n<td>CMP (May 2026)<\/td>\n<td>Rs 1,685.00<\/td>\n<\/tr>\n<tr>\n<td>52 Week High<\/td>\n<td>Rs 1,830.00<\/td>\n<\/tr>\n<tr>\n<td>52 Week Low<\/td>\n<td>Rs 1,040.00<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 11,000 Crore<\/td>\n<\/tr>\n<tr>\n<td>Trailing P\/E<\/td>\n<td>28x<\/td>\n<\/tr>\n<tr>\n<td>Analyst Consensus Target<\/td>\n<td>Rs 2,100<\/td>\n<\/tr>\n<tr>\n<td>Bull Case Target<\/td>\n<td>Rs 2,600<\/td>\n<\/tr>\n<tr>\n<td>Bear Case Target<\/td>\n<td>Rs 1,500<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Analyst_Insight_in_This_Emcure_Pharmaceuticals_Analyst_Review\"><\/span><strong>Analyst Insight in This Emcure Pharmaceuticals Analyst Review<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Senior Research Analyst <strong>Ankit Jaiswal<\/strong> flags Emcure Pharmaceuticals as a stock to watch in May 2026. At Rs 1,685.00, Ankit Jaiswal identifies key support in the Rs 1061 to Rs 1601 band and resistance near Rs 1786. He suggests watching Emcure Pharmaceuticals for a potential move toward Rs 2,100, subject to Pharmaceuticals &#8211; Branded and Global sector momentum and Nifty 50 direction. Ankit Jaiswal&#8217;s view is one input in this <strong>Emcure Pharmaceuticals analyst review<\/strong> and does not constitute a trade recommendation.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Technical_Analysis_in_This_Emcure_Pharmaceuticals_Analyst_Review\"><\/span><strong>Technical Analysis in This Emcure Pharmaceuticals Analyst Review<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>At Rs 1,685.00, EMCURE is trading within its 52-week band of Rs 1,040.00 to Rs 1,830.00. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.<\/p>\n<p>Near-term support is identified in the Rs 1061 to Rs 1601 band while resistance is seen in the Rs 1786 to Rs 1892 zone. A sustained move above Rs 1786 could open the path toward the analyst consensus target of Rs 2,100 as outlined in this <strong>Emcure Pharmaceuticals analyst review<\/strong>.<\/p>\n<p><a href=\"https:\/\/univest.in\/screeners\"><strong>Screen the best stocks on the Univest Screener.<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Support_and_Resistance_Levels\"><\/span><strong>Key Support and Resistance Levels<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Support Zone:<\/strong> Rs 1061 to Rs 1601 &#8211; investors tracking this <strong>Emcure Pharmaceuticals analyst review<\/strong> should watch for stabilisation or a bounce in this range as a potential accumulation signal for EMCURE.<\/li>\n<li><strong>Resistance Zone:<\/strong> Rs 1786 to Rs 1892 &#8211; a sustained close above Rs 1786 would be a positive breakout signal worth flagging in this <strong>Emcure Pharmaceuticals analyst review<\/strong>.<\/li>\n<li><strong>Medium-Term Target:<\/strong> The analyst consensus of Rs 2,100 represents the base-case upside scenario in this <strong>Emcure Pharmaceuticals analyst review<\/strong>.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Business_Segment_Analysis\"><\/span><strong>Business Segment Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"India_Branded_Formulations_Gynaecology_Cardiology\"><\/span><strong>India Branded Formulations (Gynaecology, Cardiology)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This is the primary revenue and margin driver for Emcure Pharmaceuticals, directly supporting the earnings trajectory toward the consensus target of Rs 2,100.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"HIV_Treatment_Drugs_Hetero_JV_Partnership\"><\/span><strong>HIV Treatment Drugs (Hetero JV Partnership)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This segment adds scale and diversification to Emcure Pharmaceuticals&#8217;s business model and is a meaningful EPS contributor through FY27 and FY28.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"International_Operations_Brazil_Canada_Europe\"><\/span><strong>International Operations (Brazil, Canada, Europe)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This represents the medium-term growth frontier for Emcure Pharmaceuticals and a key re-rating catalyst over the next 12 to 24 months.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Valuation_in_This_Emcure_Pharmaceuticals_Analyst_Review\"><\/span><strong>Valuation in This Emcure Pharmaceuticals Analyst Review<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>At Rs 1,685.00, Emcure Pharmaceuticals trades at a trailing P\/E of 28x. This <strong>Emcure Pharmaceuticals analyst review<\/strong> presents three scenarios: a bull case of Rs 2,600 on strong earnings delivery and sector tailwinds, a base case of Rs 2,100 at analyst consensus, and a bear case of Rs 1,500 if macro headwinds persist. Q1 FY27 results will be the first key checkpoint for this <strong>Emcure Pharmaceuticals analyst review<\/strong>.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Scenario<\/th>\n<th>Target Price<\/th>\n<th>Key Condition<\/th>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>Rs 2,600<\/td>\n<td>Strong earnings delivery and sector re-rating<\/td>\n<\/tr>\n<tr>\n<td>Base Case (Consensus)<\/td>\n<td>Rs 2,100<\/td>\n<td>Moderate growth, analyst consensus estimate<\/td>\n<\/tr>\n<tr>\n<td>Bear Case<\/td>\n<td>Rs 1,500<\/td>\n<td>Earnings miss or macro headwinds<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Trade_Outlook_for_Emcure_Pharmaceuticals\"><\/span><strong>Trade Outlook for Emcure Pharmaceuticals<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Based on the technical and fundamental analysis in this <strong>Emcure Pharmaceuticals analyst review<\/strong>, investors might watch EMCURE near the support zone of Rs 1061 to Rs 1601 for potential opportunities. A flag above Rs 1786 could suggest improving momentum toward Rs 2,100. This article uses watch-and-flag language only and does not constitute a trade recommendation.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_for_Emcure_Pharmaceuticals_in_FY27\"><\/span><strong>Key Risks for Emcure Pharmaceuticals in FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>A well-rounded <strong>Emcure Pharmaceuticals analyst review<\/strong> must assess downside risks. Key risks for Emcure Pharmaceuticals include a macro slowdown affecting Pharmaceuticals &#8211; Branded and Global sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in EMCURE.<\/p>\n<p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or the <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to get daily stock recommendations and expert research.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion_Emcure_Pharmaceuticals_Analyst_Review_Verdict_for_2026\"><\/span><strong>Conclusion: Emcure Pharmaceuticals Analyst Review Verdict for 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>This <strong>Emcure Pharmaceuticals analyst review<\/strong> concludes that at Rs 1,685.00, EMCURE offers a defined risk-reward with a consensus target of Rs 2,100. The 52-week range of Rs 1,040.00 to Rs 1,830.00 provides context on the current entry point. Use this <strong>Emcure Pharmaceuticals analyst review<\/strong> as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on EMCURE.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_Emcure_Pharmaceuticals_Analyst_Review_2026\"><\/span><strong>Frequently Asked Questions: Emcure Pharmaceuticals Analyst Review 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_analyst_target_for_Emcure_Pharmaceuticals_in_2026\"><\/span><strong>What is the analyst target for Emcure Pharmaceuticals in 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The analyst consensus target is Rs 2,100, with a bull case of Rs 2,600 and a bear case of Rs 1,500. This <strong>Emcure Pharmaceuticals analyst review<\/strong> recommends monitoring Q1 FY27 earnings for confirmation.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Emcure_Pharmaceuticals_a_good_investment_at_Rs_168500\"><\/span><strong>Is Emcure Pharmaceuticals a good investment at Rs 1,685.00?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At Rs 1,685.00 with a P\/E of 28x and a consensus target of Rs 2,100, this <strong>Emcure Pharmaceuticals analyst review<\/strong> is constructive for medium to long-term investors in the Pharmaceuticals &#8211; Branded and Global sector. Always consult a SEBI-registered advisor before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Emcure_Pharmaceuticalss_52-week_high_and_low\"><\/span><strong>What is Emcure Pharmaceuticals&#8217;s 52-week high and low?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The 52-week high is Rs 1,830.00 and the 52-week low is Rs 1,040.00. At Rs 1,685.00, EMCURE is positioned within this range as detailed in this <strong>Emcure Pharmaceuticals analyst review<\/strong>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_key_risks_for_Emcure_Pharmaceuticals\"><\/span><strong>What are the key risks for Emcure Pharmaceuticals?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Pharmaceuticals &#8211; Branded and Global sector, all assessed in this <strong>Emcure Pharmaceuticals analyst review<\/strong>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Where_can_I_track_live_data_for_Emcure_Pharmaceuticals\"><\/span><strong>Where can I track live data for Emcure Pharmaceuticals?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Track Emcure Pharmaceuticals&#8217;s live price and analyst targets on the Univest Screener alongside professional financial advice to complement this <strong>Emcure Pharmaceuticals analyst review<\/strong>.<\/p>\n<p><em>Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Emcure Pharmaceuticals analyst review 2026: CMP Rs 1,685.00, MCap Rs 11,000 Cr, PE 28x. Pharmaceuticals &#8211; Branded and Global sector technical levels. May 2026.<\/p>\n","protected":false},"author":28,"featured_media":91823,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-91115","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1779193465:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["82"],"rank_math_title":["Emcure Pharmaceuticals Analyst Review 2026"],"rank_math_description":["Emcure Pharmaceuticals analyst review 2026: CMP Rs 1,685.00, MCap Rs 11,000 Cr, PE 28x. Pharmaceuticals - Branded and Global sector technical levels. May 2026."],"rank_math_focus_keyword":["Emcure Pharmaceuticals Analyst Review"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["91823"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["12356"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/05\/19175400\/Emcure-Pharmaceuticals-Analyst-Review.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/91115","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=91115"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/91115\/revisions"}],"predecessor-version":[{"id":91825,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/91115\/revisions\/91825"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/91823"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=91115"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=91115"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=91115"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}